Comment on

• Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction.

  Zlotta AR, Djavan B, Marberger M, Schulman CC. Zlotta AR, et al. J Urol. 1997 Apr;157(4):1315-21. J Urol. 1997. PMID: 9120930
• Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy.

  Witherspoon LR, Lapeyrolerie T. Witherspoon LR, et al. J Urol. 1997 Apr;157(4):1322-8. J Urol. 1997. PMID: 9120931 Clinical Trial.
• Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.

  Smith JA Jr, Lange PH, Janknegt RA, Abbou CC, deGery A. Smith JA Jr, et al. J Urol. 1997 Apr;157(4):1329-34. J Urol. 1997. PMID: 9120932 Clinical Trial.